Article
BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.
Cancer research - 1 Aug 2008
Friday Bret B, Yu Chunrong, Dy Grace K, Smith Paul D, Wang Liang, Thibodeau Stephen N, Adjei Alex A
Abstract excerpt
AZD6244 (ARRY 142886) is a potent and selective mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor currently in early clinical trials. We examined the activity of AZD6244 in a panel of non-small cell lung cancer and a panel of cell lines representing many cancer types using in vitro growth assays. AZD6244 induced G(0)-G(1) cell cycle arrest in sensitive cell...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
